- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04195399
Studie nového léku, Nirogacestat, pro léčbu desmoidních nádorů, které nelze odstranit chirurgicky
Studie bezpečnosti, farmakokinetiky a účinnosti inhibitoru y-sekretázy, nirogacestatu (PF-03084014) u dětí a dospívajících s progresivními, chirurgicky neresekovatelnými desmoidními nádory
This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Přehled studie
Postavení
Podmínky
Detailní popis
PRIMARY OBJECTIVES:
I. To estimate the 2-year progression-free survival (PFS) rate in patients with progressive, surgically unresectable desmoid tumor treated with nirogacestat.
II. To describe the toxicities of nirogacestat in children and adolescents with desmoid tumor.
III. To characterize the pharmacokinetics (PK) of nirogacestat in children and adolescents.
SECONDARY OBJECTIVE:
I. To determine the objective tumor response rate (ORR) of nirogacestat in children and adolescents with progressive, surgically unresectable desmoid tumor.
EXPLORATORY OBJECTIVES:
I. To collect blood, archival tumor samples and on-study/post-treatment tumor samples (if available) from patients enrolled on this trial to correlate various CTNNB1 and APC gene mutations and genomic signatures with tumor response and PFS.
II. To explore the effect of nirogacestat on immune cells and immunoglobulin levels in the peripheral blood.
III. To collect blood samples for banking at baseline, during treatment, and at the time of progression for future research.
IV. To compare assessment of tumor response using Response Evaluation Criteria in Solid Tumors (RECIST), World Health Organization (WHO) criteria, and T2 and volumetric changes using magnetic resonance imaging (MRI).
V. To utilize a tool developed to specifically assess patient reported outcomes (PROs) in adult patients with desmoid tumor (GOunder/DTRF DEsmoid Symptom/Impact Scale [GODDESS]) and the Patient Reported Outcomes Measurement Information System (PROMIS) to explore the relationship between PROs and tumor response and PFS.
OUTLINE:
Patients receive nirogacestat orally (PO) twice daily (BID) on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) and computed tomography (CT) or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study.
After completion of study treatment, patients are followed up at 30 days.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
New South Wales
-
Westmead, New South Wales, Austrálie, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Austrálie, 4101
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Austrálie, 6009
- Perth Children's Hospital
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
-
-
-
-
Christchurch, Nový Zéland, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Nový Zéland, 1145
- Starship Children's Hospital
-
-
-
-
-
San Juan, Portoriko, 00926
- University Pediatric Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Spojené státy, 36604
- USA Health Strada Patient Care Center
-
-
Arizona
-
Mesa, Arizona, Spojené státy, 85202
- Banner Children's at Desert
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Spojené státy, 90242
- Kaiser Permanente Downey Medical Center
-
Loma Linda, California, Spojené státy, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Spojené státy, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, Spojené státy, 90095
- Mattel Children's Hospital UCLA
-
Oakland, California, Spojené státy, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Spojené státy, 94611
- Kaiser Permanente-Oakland
-
Palo Alto, California, Spojené státy, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Spojené státy, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Spojené státy, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Spojené státy, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Spojené státy, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06106
- Connecticut Children's Medical Center
-
-
Delaware
-
Wilmington, Delaware, Spojené státy, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Spojené státy, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Gainesville, Florida, Spojené státy, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Spojené státy, 32207
- Nemours Children's Clinic-Jacksonville
-
Orlando, Florida, Spojené státy, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Spojené státy, 32803
- AdventHealth Orlando
-
St. Petersburg, Florida, Spojené státy, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Spojené státy, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Spojené státy, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Spojené státy, 60611
- Lurie Children's Hospital-Chicago
-
Peoria, Illinois, Spojené státy, 61637
- OSF Children's Hospital of Illinois
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Riley Hospital for Children
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Spojené státy, 70118
- Children's Hospital New Orleans
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Bethesda, Maryland, Spojené státy, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Spojené státy, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- C S Mott Children's Hospital
-
East Lansing, Michigan, Spojené státy, 48823
- Michigan State University
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Spojené státy, 49007
- Bronson Methodist Hospital
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Spojené státy, 63141
- Mercy Hospital Saint Louis
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Spojené státy, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Spojené státy, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Spojené státy, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Spojené státy, 89502
- Renown Regional Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Spojené státy, 07601
- Hackensack University Medical Center
-
-
New York
-
Albany, New York, Spojené státy, 12208
- Albany Medical Center
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Spojené státy, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Syracuse, New York, Spojené státy, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Spojené státy, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Spojené státy, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Spojené státy, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Spojené státy, 45404
- Dayton Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Spojené státy, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Spojené státy, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, Spojené státy, 29605
- BI-LO Charities Children's Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Spojené státy, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Spojené státy, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Spojené státy, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Spojené státy, 78723
- Dell Children's Medical Center of Central Texas
-
Dallas, Texas, Spojené státy, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
El Paso, Texas, Spojené státy, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Spojené státy, 76104
- Cook Children's Medical Center
-
Houston, Texas, Spojené státy, 77030
- UT MD Anderson Cancer Center
-
San Antonio, Texas, Spojené státy, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84113
- Primary Children's Hospital
-
-
Virginia
-
Norfolk, Virginia, Spojené státy, 23507
- Children's Hospital of The King's Daughters
-
Roanoke, Virginia, Spojené státy, 24014
- Carilion Children's
-
-
Wisconsin
-
Madison, Wisconsin, Spojené státy, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Children's Hospital of Wisconsin
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Patients must be > 12 months and < 18 years of age at the time of enrollment
-
Patients must have a body surface area of > 0.3 m^2 at the time of enrollment
-
Existing or recurrent desmoid tumor that is deemed not amenable to surgery without significant morbidity and progressed by >= 10% as assessed by RECIST version (v)1.1 within the 6-month period prior to study enrollment
- Patients must have had histologic verification of the desmoid tumor
- Patients must have measurable disease by RECIST v1.1 criteria
- Patient must have received at least one prior course of systemic therapy for desmoid tumor
-
Patients must have a Lansky (for patients =< 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of >= 50. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing performance score
-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, surgery or radiotherapy prior to entering this study. Patients may not be using or anticipate using these treatments after the observed progression or within the time period stated below
- Cytotoxic chemotherapy: must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea)
- Small molecule tyrosine kinase inhibitors (e.g., sorafenib, pazopanib, imatinib), rapalogs (e.g., temsirolimus, everolimus, sirolimus) or anti estrogen therapy (e.g., tamoxifen): may not have received within 28 days prior to the first dose of study treatment
- Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1
- Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent
- Local regional tumor directed therapy, including, but not limited to small port radiation therapy (RT), radiofrequency ablation, cryotherapy, surgery: at least 2 weeks since these therapies and all toxicity must have resolved to grade =< 1. If prior craniospinal RT or if >= 50% radiation of pelvis then >= 6 months must have elapsed. If other substantial bone marrow (BM) radiation, then >= 6 weeks must have elapsed
- Stem cell transplant (SCT): No evidence of active graft versus (vs.) host disease. For allogeneic SCT, >= 6 months must have elapsed
- No prior gamma-secretase, Notch or beta-catenin inhibitor
- Investigational drugs: must not have received investigational drug within 4 weeks of study entry, and all toxicities related to prior therapy must be resolved to grade =< 1 or baseline
-
Concomitant Medication Restrictions
- Growth factor(s): must not have received within 1 week of entry onto this study
- Patients who are currently receiving drugs that are strong inducers or moderate or strong inhibitors of CYP3A4 are not eligible. Strong inducers or moderate or strong inhibitors of CYP3A4 are not allowed from 14 days prior to enrollment to the end of protocol therapy. Note: CYP3A4 inducing anti-epileptic drugs on a stable dose, are allowed
- Must not be receiving non-steroidal anti-inflammatory drugs (NSAIDs) as treatment for desmoid tumor after the observed progression and patient agrees to not use NSAIDs while on study. Occasional use (defined as =< 3 times per week) for treatment of pain is permitted
-
Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to enrollment)
-
Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to enrollment)
-
Hemoglobin >= 9.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to enrollment)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows (within 7 days prior to enrollment):
- Age: Maximum serum creatinine (mg/dL)
- Age: 1 to < 2 years; Maximum serum creatinine (mg/dL): 0.6 (male and female)
- Age: 2 to < 6 years; Maximum serum creatinine (mg/dL): 0.8 (male and female)
- Age: 6 to < 10 years; Maximum serum creatinine (mg/dL): 1 (male and female)
- Age: 10 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male and female)
- Age: 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)
- Age: >= 16 years; Maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)
-
Adequate liver function defined as:
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (unless secondary to previously diagnosed Gilbert's syndrome) (within 7 days prior to enrollment)
-
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L (within 7 days prior to enrollment)
-
Adequate cardiac function defined as:
- Corrected QT (QTc) interval < 470 ms
- No history of congenital or acquired prolonged QTc syndrome
- No history of clinically significant cardiac arrhythmias, congestive heart failure, stroke or myocardial infarction within 6 months prior to study entry
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Active or chronic infection within 7 days prior to study entry
-
Presence of non-healing fracture
- Note: patients with pathologic fracture related to tumor are eligible
-
Use of corticosteroids within 21 days of enrollment, except in the following situations:
- Physiologic steroid replacement for adrenal insufficiency
- Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption
- Short course (=< 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen), or exacerbation of asthma
-
Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication, prior surgical procedures affecting absorption (e.g., gastric bypass), malabsorption syndrome, and active peptic ulcer disease)
-
Patients with ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction
-
Known active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
-
Patients with a prior history of malignancy, with the exceptions of desmoid tumor(s) and non-melanoma skin cancer, who are not in remission for more than 3 years
-
Patients who are unable to swallow tablets. Tablets must not be crushed or chewed. Administration of nirogacestat via gastrostomy tube or nasogastric tube is not allowed
-
Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
-
Sexually active female patients of reproductive potential who have not agreed to use 1 method of highly effective contraceptive (including copper-containing intrauterine device, condom with spermicidal foam/gel/film/cream/suppository, bilateral tubal ligation, established use of inserted, injected or implanted hormonal method of contraception, abstinence, or male sterilization) for the duration of their study participation and for at least 6 months after last dose of nirogacestat. A second form of contraception (i.e. barrier method) is required for patients who are using hormonal contraception as nirogacestat may reduce the efficacy of hormonal contraceptives
-
Sexually active male patients of reproductive potential who have not agreed to use a condom and their female partner who have not agreed to use one of the highly effective methods of contraception mentioned above during treatment and for at least 90 days after the last dose of nirogacestat
-
Female patients who are breastfeeding
-
Female patients who are pregnant. These patients are excluded because there is no available information regarding the effects of nirogacestat on the developing human fetus and inhibition of gamma-secretase is known to be teratogenic
-
Female patients of childbearing potential unless a negative pregnancy test result has been obtained
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Treatment (nirogacestat)
Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and CT or MRI on study. Patients may also undergo x-ray imaging and blood sample collection on study. |
Ancillary studies
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Undergo CT
Ostatní jména:
Undergo MRI
Ostatní jména:
Ancillary studies Undergo ECHO
Ostatní jména:
Undergo x-ray
Ostatní jména:
Given PO
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free survival (PFS)
Časové okno: Up to 2 years from study entry
|
The Kaplan-Meier method will be used to estimate the 2-year PFS defined as the time from study entry until disease progression or death from any cause. |
Up to 2 years from study entry
|
|
Percentage of patients experiencing grade 3+ adverse events (AE)
Časové okno: Up to 6 years from study entry
|
Percentage of patients experiencing grade 3 or higher AEs will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All grade 1 and 2 toxicities observed in > 5% of participants and deemed related to study drug will be reported. |
Up to 6 years from study entry
|
|
Pharmacokinetic (PK) parameter: systemic exposure
Časové okno: Up to Cycle 3 (each cycle lasts 28 days)
|
PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations. |
Up to Cycle 3 (each cycle lasts 28 days)
|
|
PK parameter: drug clearance
Časové okno: Up to Cycle 3 (each cycle lasts 28 days)
|
PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations. |
Up to Cycle 3 (each cycle lasts 28 days)
|
|
PK parameter: half-life
Časové okno: Up to Cycle 3 (each cycle lasts 28 days)
|
PK parameters of nirogacestat will be defined to quantify systemic exposure, drug clearance, terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics, including means, medians, ranges, and standard deviations. |
Up to Cycle 3 (each cycle lasts 28 days)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Objective response rate
Časové okno: Up to 24 months
|
Defined by the rate of a complete response or partial response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to 24 months
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
CTNNB1 and APC gene mutations and genomic signatures
Časové okno: Up to 2 years
|
The chi-square test will be used to assess the correlation of CTNNB1 and APC gene mutations and genomic signatures with tumor response, and the long-rank test will be used to assess the correlation of CTNNB1 and APC gene mutations and genomic signatures with PFS. |
Up to 2 years
|
|
Changes in the levels of each of the lymphocyte subsets and immunoglobulins
Časové okno: Up to 2 years
|
Lymphocyte subsets include CD3 (total T cells), CD3+CD4+ (T helper cells), CD3+CD8+ (T cytotoxic cells), CD3+HLA-DR+ (activated T cells) percentages and absolute counts and CD4:CD8 ratio. The chi-square test will be used to assess the correlation of the levels of lymphocyte and immunoglobulin with tumor response, and the Cox regression will be used to assess the correlation of the levels of lymphocyte and immunoglobulin with PFS. |
Up to 2 years
|
|
Response assessments by the RECIST criteria
Časové okno: Up to 2 years
|
Assesses tumor response based primarily on changes in measurable tumor lesions on imaging using RECIST 1.1. |
Up to 2 years
|
|
Response assessment by the World Health Organization (WHO) criteria
Časové okno: Up to cycle 2 years
|
Assesses tumor response using the product of two perpendicular tumor measurements according to the WHO criteria. |
Up to cycle 2 years
|
|
Patient reported outcomes (PROs)
Časové okno: Up to 2 years
|
The chi-square test will be used to assess the correlation of PROs summary scores with tumor response, and the Cox regression will be used to assess the correlation of PROs summary scores with PFS. Correlation between PRO summary scores using Patient Reported Outcomes Measurement Information System and GOunder/DTRF DEsmoid Symptom/Impact Scale will be assessed by performing inferences on the Pearson correlation coefficients. |
Up to 2 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Fariba Navid, Children's Oncology Group
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary
- Novotvary podle histologického typu
- Novotvary, pojivové a měkké tkáně
- Novotvary, pojivová tkáň
- Novotvary, vazivová tkáň
- Fibrom
- Desmoidní nádory
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Fyzické jevy
- Vybavení a potřeby
- Techniky chemie, analytické
- Analýza spektra
- Elektromagnetické jevy
- Magnetické jevy
- Elektromagnetické záření
- Záření
- Záření, ionizující
- Manipulace se vzorkem
- Magnetická rezonanční spektroskopie
- Rentgenové paprsky
- Phantomy, zobrazování
- Nirogacestat
Další identifikační čísla studie
- ARST1921
- U10CA180886 (Grant/smlouva NIH USA)
- ARST1921 (Jiný identifikátor: CTEP)
- NCI-2019-07498 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- ARST1921 (Jiný identifikátor: Children's Oncology Group)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .